Akili Inc (AKLI)

[Monksdream]

5-day, five-minute bar/volume for AKLI

[Monkmojo]

For sure. Then the partnership with Roblox is HUGE

Roblox, $23 billion dollar company and growing, will want that FDA label
for even more explosive growth.



For the full article:

https://pharmaphorum.com/news/akili-partners-with-gaming-giant-roblox-on-adhd-therapy-delivery/

[trendzone]

Big time investor Temasek Holding put on and now has 13.5% stake in the company, with it being below $6.00,and was over thirty bucks when IPOed last week,anyone selling at this point would have to be a clueless fool.

[trendzone]

Most likely the case,all the market pumpers threw everything out the window on Fridays huge selloff,probably were getting out before they thought they would get margin calls on their accounts, with yesterday's big news of well known investments firm having a 13.5 stake in the company it was having a good day,was at one point up like $1.80,until the market turned everything into an ugly mess, as the market titanic was sinking I rescued a bunch of shares as the panicked kids jumped over board.

[Monkmojo]

Nice write up on Akili:



Less than two years after scoring its first FDA clearance, Akili Interactive is betting big on its digital therapeutic technology.

The Massachusetts-based company has signed a reverse-merger deal with Social Capital Suvretta Holdings Corp. I—a special purpose acquisition company (SPAC) that completed a $220 million IPO last summer—to make its own public debut. Once the deal is complete, the combined company will operate under the Akili name and trade on the Nasdaq as “AKLI.”

At the close of the transaction, the newly public Akili is expecting to boast a total equity value of about $1 billion. The transaction is forecast to be finalized sometime around the middle of this year.

RELATED: Prescription video game developer Akili snags $160M to launch ADHD treatment

According to the startup, the SPAC deal will help ramp up the commercial launch of EndeavorRx, Akili’s FDA-cleared and CE marked program designed to improve attention function in children with attention deficit hyperactivity disorder (ADHD).

Plus, the proceeds from the transaction and Akili’s subsequent public debut will help speed up development of its other digital therapeutics to treat symptoms associated with a range of neuropsychiatric diseases including multiple sclerosis, autism, depression and more.

Those proceeds are expected to tally up to $412 million, including a $162 million private investment round from several new and existing backers that Akili is planning to close in the lead-up to the reverse merger.

The bulk of the private round, $100 million, will come from Social Capital, parent company of Akili’s SPAC partner, while the remaining $62 million has already been pledged by a group of investors that includes Averill Strategy, Apeiron Investment Group, Temasek, Polaris Partners, Evidity Health Capital, Jazz Venture Partners, Omidyar Technology Ventures and PureTech Health, which helped establish Akili in 2011.

RELATED: Akili expands its prescription video game portfolio with $37M offer for Tali's attention-improving tech

Akili’s EndeavorRx technology in 2020 became the first prescription video game cleared by the FDA. The system tasks children with ADHD between the ages of eight and 12 with working their way through multiple levels of an interactive game filled with sensory stimuli and motor challenges that have been clinically proven to activate the parts of the brain linked to attention.

Clinical trial results included in the FDA submission showed that playing the game—which relies on an internal algorithm to constantly adapt to fit each player’s needs and abilities—can alleviate ADHD symptoms, with about 50% of parents reporting improvements in their child’s day-to-day symptoms and nearly 60% saying the game improved attention.

Since garnering the groundbreaking FDA nod, Akili has proceeded on a path of rapid growth. Last May, it blew its own previous fundraising tally out of the water, closing a series D funding round worth $110 million. And the following August, it shelled out about a third of that amount to license a new portfolio of attention-improving digital therapeutics from Tali Digital.

[Monkmojo]

0.80¢ under the VWAP . It looks like heavy dark pool trades brought on by the DOW plummetting south today.
Rebound next week.

[erik007tc]

Yea so true… sellers fading though, hopefully next week we go over$6

[trendzone]

Total corruption manipulation at the highest level,they need a good squeezing over six bucks.

[trendzone]

Big time investor Temasek Holding put on and now has 13.5% stake in the company, with it being below $6.00,and was over thirty bucks when IPOed last week,anyone selling at this point would have to be a clueless fool.

[heyitsmeagain]

BOOM

[erik007tc]

Double my position… no worries this will BOOM! MM’s playing and will let this ride soon.

[cityimport]

DAMN!

This turned to be worst than the OTC SCAMs

[janetcanada]

AKLI- Was Not Expecting this to happen!....Lets hope to see a Turnaround......https://nz.finance.yahoo.com ›

Best of Luck CoaptainScotty!...
Un Sorriso
janet

[captainscotty]

#AKLI: HEY JANET.....CRAZY TIMES... GO JANET

[Invest-in-America]

The "BOEING MAX" effect.

[Invest-in-America]

What did P.T. Barnum say??? "There's a SUCKER born every minute!" (Or, was it, "Stupid is, as stupid DOES"???)

[BCNstocks]

Yep, you're right. I think it hit around $60 in pre-market.

[Invest-in-America]

Or at the Mount Everest GAP-UP this morning --- even WORSE!! WOW!! (Heck, I'm goin' back to VEGAS, & work the CRAPS tables!!)

[Invest-in-America]

Well, I guess I was WRONG on this little puppy!!! GEEEEEZUUUS J. CHRISTOOOOO!!! Next time I ponder a stock pick, I'm gonna be workin' my ROSARY BEADS real hard!!! (I'm a Catholic --- still under treatment for that.)

[BCNstocks]

From the looks of it AKLI turned into an absolute pos. Now close to $12. Feel bad for the people buying in the $40s ah on Friday.

[cityimport]

What happened here?

Now 16.00 down big from 42.00

[BCNstocks]

They keep halting and pushing down, but I think we will see a big move back up once sellers out. Less than 300k float.

[Carjockey2]

I am ready!!!

[Invest-in-America]

AKLI: Might be somethin' like THIS, today??? (Just a wild-&-crazy GUESS on my part.)

[BCNstocks]

$AKLI is going to be awesome today! I got in on Friday when it was still $DNAA.

[crudeoil24]

42.00 up 198%

[BRATTLECAM]

Whoop-Whoop-Whoop Yankees Win-Yankees Winnnnnn!

[crudeoil24]

First-and-only FDA-cleared video game-based digital therapeutic.

[crudeoil24]

Key Investment Highlights:

Patented and clinically validated technology platform. Developed with the collaboration of cognitive neuroscientists and mobile game developers, Akili’s proprietary technology is designed to target key neural systems underlying specific cognitive functions through adaptable, personalized closed-loop algorithms. The technology is clinically validated, using recognized endpoints, and delivered through smartphones or other mobile devices.
First-and-only FDA-cleared video game-based digital therapeutic. Anticipated to launch in the second half of 2022, EndeavorRx® is the first and only prescription video game treatment with FDA clearance and a CE mark (designating it has met European health, safety, performance, and environmental requirements) in pediatric ADHD. EndeavorRx® has been validated through multiple clinical trials, including large randomized, controlled trials demonstrating improved patient outcomes.
Large and growing market opportunity. Tens of millions of people worldwide live with cognitive health issues, and many are actively searching for better solutions. With EndeavorRx®, Akili is initially targeting the approximately $10 billion U.S. ADHD market. EndeavorRx® will first launch for the FDA-cleared 8 to 12-year-old pediatric population. Akili is also seeking to expand into other U.S. ADHD populations, including younger children (3 to 7 years old), teens, and adults, while simultaneously working with a partner to gain approval as a treatment for pediatric ADHD in Japan.
Strong clinical rigor. Akili has completed 20 clinical trials across 2,900 patients and nine disease populations. In addition, Akili’s clinical studies and data have been published in 16 leading peer-reviewed journals.
Robust research and clinical pipeline. Akili has a strong development pipeline, initially focused on treatments for cognitive impairments across nine patient populations. In addition, Akili is progressing early discovery for two new platform technologies to address additional cognitive impairments and facilitate broader reach across disease spectrums. Akili is poised to begin pivotal studies in multiple indications where proof-of-concept has been achieved, including additional ADHD populations, ASD, MS, and MDD.

[crudeoil24]

Shares of blank-check company Social Capital Suvretta Holdings Corp. I rose 56% to $14.81 after it completed its combination with digital medicine company Akili Interactive.

According to a Nasdaq alert, the deal closed Friday, and the company's new name, Akili Inc., and new symbol, AKLI, will be effective Monday.

[crudeoil24]

Electronic medicine > Where is old timer Ozzy Osborne!

[crudeoil24]

Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches. Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required. Akili is based in Boston, Massachusetts.

[Carjockey2]

Whoop whoop whoop

$AKLI

[TheFinalCD]

$AKLI

[TheFinalCD]

https://equityzen.com/company/akili/

[janetcanada]

AKLI- Interesting......

Wishing a great day
janet

[crudeoil24]

>>>>> SOFTWARE- BASED MEDICINE <<<<<

[Renee]

AKLI added to the Nasdaq:

https://www.sec.gov/Archives/edgar/data/1850266/000119312522225468/d191816dex991.htm

[crudeoil24]

Social Capital Suvretta Holdings Corp. I Up 56% After Akili Deal Closes
2:12 pm ET August 19, 2022 (Dow Jones)
By Josh Beckerman


Shares of blank-check company Social Capital Suvretta Holdings Corp. I rose 56% to $14.81 after it completed its combination with digital medicine company Akili Interactive.

According to a Nasdaq alert, the deal closed Friday, and the company's new name, Akili Inc., and new symbol, AKLI, will be effective Monday.


Write to Josh Beckerman at [e-mail]


(END) Dow Jones Newswires

August 19, 2022 14:12 ET (18:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

[crudeoil24]

Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I
5:25 pm ET August 19, 2022 (BusinessWire) Print
--Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline

Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (Nasdaq: DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. ("Akili"), is expected to start trading on The Nasdaq Capital Market ("Nasdaq") under the new ticker symbol "AKLI" on August 22, 2022.

Akili raised more than $163 million from the transaction, before deducting transaction expenses and advisory fees, which, together with cash on hand, the company expects will be sufficient to fund at least 24 months of business operations, excluding any contributions from EndeavorRx(R) revenues. Proceeds from the transaction will fund the commercial launch of EndeavorRx, a first-of-its-kind, U.S. Food and Drug Administration (FDA) cleared and Conformite Europeenne (CE) Mark certified prescription digital therapeutic for pediatric attention-deficit/hyperactivity disorder (ADHD) (see full indication and safety information below), as well as potential expansion into additional ADHD patient populations. Proceeds will also support the advancement of the company's late-stage pipeline of product candidates designed to treat neuropsychiatric diseases, including autism spectrum disorder (ASD), multiple sclerosis (MS), and major depressive disorder (MDD). SCS shareholders approved the transaction at a general meeting on August 18, 2022.

Eddie Martucci, CEO of Akili, said: "Today's milestone reflects the combined efforts of the committed Akili team and SCS who together made this defining moment possible. Millions of people worldwide live with cognitive impairment without effective treatments. I am proud of our talented employees - leaders in neuroscience, entertainment and consumer technology - who are propelling Akili's innovative software-based therapeutics forward to deliver an engaging, immersive experience. I am extremely excited about what's ahead as we begin to scale and serve patients in need."

Chamath Palihapitiya, Chairman and CEO of SCS, commented: "With this milestone completed, Akili has a number of others ahead, including its upcoming commercial launch of EndeavorRx and a strong clinical pipeline of breakthrough digital therapeutic candidates that have the potential to treat a host of cognitive impairments. I look forward to working with Eddie and the Akili team as they enter this new and exciting chapter."

A commercial-stage company, Akili develops digital therapeutics that combine science and technology to address cognitive impairments in patients, representing a new category of software-based medicine that is designed to directly target brain function and is delivered through engaging consumer entertainment. Cognitive impairments - including inattention, poor concentration, memory loss, difficulties learning new skills, and difficulties with decision making - are in aggregate among the largest unmet medical needs and are increasingly recognized as contributing to or associated with dozens of chronic diseases and acute illnesses.

Scheduled for U.S. launch in the fourth quarter of 2022, EndeavorRx is the first-ever prescription video game and the first-ever FDA-cleared digital therapeutic indicated to improve attention function in children with ADHD (see full indication below). In addition, the company's patented and clinically validated Selective Stimulus Management Engine (SSME(TM)) has demonstrated proof-of-concept efficacy in controlled trials targeting attention and cognitive dysfunction in ASD, MS, and MDD.

Akili CEO and co-founder Eddie Martucci will continue to lead Akili's management team and serve on Akili's board. Chamath Palihapitiya, Chairman and CEO of SCS, will chair Akili's board. Akili's board also includes William ("BJ") Jones, Jr., Chief Commercial Officer of Biohaven Pharmaceuticals Holding Company Ltd.; Christine Lemke, Co-Chief Executive Officer and Director of Evidation Health, Inc.; Kenneth Ehlert, former Chief Scientific Officer of UnitedHealth Group; Bharatt Chowrira, Ph.D., J.D., president of PureTech Health plc.; and Adam Gazzaley, M.D., Ph.D., Akili co-founder, David Dolby Distinguished Professor of Neurology, Physiology, and Psychiatry and the Founder & Executive Director of Neuroscape at the University of California, San Francisco.

Advisors

Morgan Stanley & Co. LLC ("Morgan Stanley") and Cowen and Company, LLC ("Cowen") served as financial advisors to Akili. Morgan Stanley, Credit Suisse, and Cowen served as co-placement agents to SCS with respect to the portion of the PIPE financing raised from non-insider qualified institutional buyers and institutional accredited investors. Morgan Stanley, Credit Suisse, and Cowen did not act as agents or participate in any role with respect to, and did not earn any fees from, the portion of the PIPE financing raised from insiders and individual investors. Credit Suisse and Cowen served as capital markets advisors to Akili. BofA Securities, Inc. served as capital markets advisor to SCS. Goodwin Procter LLP served as legal counsel to Akili. Wachtell, Lipton, Rosen & Katz served as legal counsel to SCS. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to the PIPE placement agents.

EndeavorRx Indication and Overview

EndeavorRx is the first-and-only FDA-cleared treatment delivered through a video game experience. EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA(R)) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child's medication. The most common side effect observed in children in EndeavorRx's clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child's health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.

About Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine - medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili's platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili's belief that effective medicine can also be fun and engaging, Akili's products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

About Social Capital Suvretta Holdings Corp. I

Social Capital Suvretta Holdings Corp. I was led by Chamath Palihapitiya and Kishen Mehta and was a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was focused on businesses operating in the biotechnology industry and within the neurology subsector. To learn more about Social Capital Suvretta Holdings, visit https://www.socialcapitalsuvrettaholdings.com/.

Forward-Looking Statements

This communication may contain certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions and include statements regarding Akili's expectations for EndeavorRx and digital medicine, the development of its platform and advancement of late-stage pipeline product candidates designed to treat neuropsychiatric diseases, including ASD, MS) and MDD, expectations and timing regarding the commercial launch of EndeavorRx and plans for the potential expansion of EndeavorRx into additional ADHD populations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Akili to successfully commercialize EndeavorRx and continue to advance its clinical development pipeline, (ii) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees, (iii) the evolution of the markets in which Akili competes, (iv) the ability of Akili to defend its intellectual property and satisfy regulatory requirements, (v) the impact of the COVID-19 pandemic on Akili's business, (vi) Akili's expectations regarding its market opportunities, (vii) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Akili operates and (viii) the timing and results expected from Akili and its partners' clinical trials. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties proxy statement/prospectus filed with the SEC on July 21, 2022, under the heading "Risk Factors," and other documents that SCS filed or Akili has filed or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Akili assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Akili gives no assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220819005385/en/

SOURCE: Akili, Inc.">

Akili
Julie DiCarlo
[e-mail]

Social Capital Suvretta
Reze Wong
[e-mail]

FGS Global
[e-mail]
comtex tracking
COMTEX_412648447/1006/2022-08-19T17:25:00